title: Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly.
abstract: Annual circulation of influenza virus coincides with a peak in cardiovascular and pneumonia mortality/morbidity. This study aimed to determine the effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisation due to acute coronary syndrome (ACS), cerebrovascular accident (CVA) and pneumonia in the elderly. Three case-control studies were performed during the 2004-2005 influenza season in three health districts in Valencia, Spain (total elderly [>64 years of age] population: n=105,454). Controls were patients admitted for an acute surgical process or trauma within 10 days of case admission. In total, 159 patients were hospitalised for ACS, 148 for CVA and 242 for pneumonia. The risk of hospitalisation after the start of the influenza season was significantly lower in vaccinated patients compared with non-vaccinated patients (adjusted odds ratios: 0.13 [P=0.013] for ACS; 0.07 [P=0.007] for CVA; 0.31 [P=0.005] for pneumonia). During peak virus circulation, vaccination with MF59-adjuvanted subunit influenza vaccine was associated with an 87% relative risk reduction in hospitalisation for ACS, 93% for CVA, and 69% for pneumonia.
authors: Fundación de la Sociedad Valenciana de Medicina de Familia y Comunitaria, Valencia, Spain. jpuigb@terra.es
authors: Joan
authors: J
authors: Puig-Barberà
authors: Javier
authors: J
authors: Díez-Domingo
authors: Angel Belenguer
authors: AB
authors: Varea
authors: Germán Schwarz
authors: GS
authors: Chavarri
authors: José A Lluch
authors: JA
authors: Rodrigo
authors: Santiago Pérez
authors: SP
authors: Hoyos
authors: David González
authors: DG
authors: Vidal
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000368:Aged; D000369:Aged, 80 and over; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000517:prevention & control; D016022:Case-Control Studies; D002561:Cerebrovascular Disorders / Q000453:epidemiology / Q000517:prevention & control; D006760:Hospitalization; D006801:Humans; D007252:Influenza Vaccines / Q000008:administration & dosage*; D032541:Mass Vaccination / Q000706:statistics & numerical data; D011014:Pneumonia / Q000453:epidemiology / Q000517:prevention & control; D011136:Polysorbates / Q000008:administration & dosage*; D012307:Risk Factors; D013030:Spain / Q000453:epidemiology; D013185:Squalene / Q000008:administration & dosage*; D022223:Vaccines, Subunit / Q000008:administration & dosage
chemical_list: D000276:Adjuvants, Immunologic; D007252:Influenza Vaccines; C089950:MF59 oil emulsion; D011136:Polysorbates; D022223:Vaccines, Subunit; D013185:Squalene